Sinovac palalawigin ang paggamit ng COVID vaccine sa 3-17 anyos

Sinovac palalawigin ang paggamit ng COVID vaccine sa 3-17 anyos

July 7, 2021 @ 9:02 AM 1 year ago


MANILA, Philippines – Nag-apply ang Chinese drug firm Sinovac Biotech sa Food and Drug Administration (FDA) na palawigin ang paggamit ng kanilang bakuna kontra coronavirus disease (COVID-19) sa mga may edad tatlo hanggang 17.

“The Sinovac, just this afternoon (July 6), they already applied for an amendment of their EUA to include children. In this case, children from three to 17 years old,” sinabi ni FDA Director-General Rolando Enrique Domingo sa Cabinet briefing.

“This is another potential vaccine that can be used for the pediatric age group,” dagdag ng opisyal.

Sa kasalukuyan, ginagamit ang Sinovac vaccine sa may edad 18 pataas.

Kamakailan, pinayagan ng FDA ang Pfizer-BioNtech na gamitin ang bakuna nito sa may edad 12 pataas.

“Our vaccine experts are now taking a look at the data and of course asking questions to the proponents and getting more information,” saad ng FDA chief.

“So ito ay inaaral natin within the month—-to see if we will be able to allow the use of Sinovac in children,” aniya pa.

Samantala, pinalawig ang interval ng pagtanggap ng dalawang dose ng Sputnik V vaccine hanggang 42 araw.

“Walang problema kung ma-delay po ang second dose but if we give it within 42 days, we have enough reason to believe that the results are going to be very good,” punto nito.

Sa kasalukuyan, wala pang aplikasyon ng EUA ang Novavax para sa bakuna nito.

“Hinihintay lang natin na ma-complete nila yung documents. We will be going to process that as quickly as we can so that we will have another possible source of vaccines,” ayon pa sa opisyal. RNT/ELM